Abstract #4140

Development of the oligomeric amyloid-beta targeted MRI contrast agents to diagnose the early stage of Alzheimer’s disease

Geon-Ho Jahng¹, Sang-Tae Kim², Peter Verwilst³, Hyug-Gi Kim⁴, Jee-Hyun Cho⁵, Kwan Soo Hong⁵, Ki Woong Kim², Jong Seung Kim³, Wook Jin¹, Eui Jong Kim⁶, and Dal Mo Yang¹

¹Radiology, Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of, ²Bundang Hospital of Seoul National University, Kyunggeedo, Korea, Republic of, ³Korea University, Seoul, Korea, Republic of, ⁴Kyung Hee University, Seoul, Korea, Republic of, ⁵Korea Basic Science Institute, Cheongju, Korea, Republic of, ⁶Radiology, Kyung Hee University Hospital, Seoul, Korea, Republic of

A new T1 molecular MRI contrast agent specifically designed to be specific for oligomeric Aβ was developed by combining the commercially available gadolinium (Gd)-Dota with an oligomeric Aβ-specific DNA aptamer. We confirmed the protein size with Aβ polymerization in aspect of molecular masses when polymers were formed. We performed the following experiment in the cell level and AD-model mice. We identified a particular region with a significantly distinct T1 MRI signal, allowing for distinguishing Alzheimer's disease model mice from non-Tg mice.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.